
  
    
      
        
        Highly_NNP active_JJ antiretroviral_NN therapy_NN (_( HAART_NNP )_) for_IN the_DT treatment_NN of_IN individuals_NNS infected_VBN
        by_IN HIV-_NNP 1_CD is_VBZ limited_VBN by_IN high_JJ costs_NNS ,_, drug_NN resistance_NN ,_, and_CC drug-related_JJ toxicities_NNS ._. This_DT has_VBZ
        led_VBN researchers_NNS to_TO investigate_VB new_JJ treatment_NN options_NNS ,_, including_VBG ways_NNS to_TO boost_VB immune_JJ
        responses_NNS to_TO better_JJR control_NN HIV_NNP ._. One_CD such_JJ approach_NN has_VBZ been_VBN termed_VBN supervised_JJ treatment_NN
        interruption_NN (_( STI_NNP )_) —_NN in_IN which_WDT HAART_NNP is_VBZ intermittently_RB stopped_VBN once_RB viral_JJ load_NN has_VBZ been_VBN
        reduced_VBN to_TO a_DT low_JJ level_NN ,_, in_IN order_NN to_TO boost_VB natural_JJ immunity_NN by_IN brief_JJ exposure_NN to_TO virus_NN ._. The_DT
        goal_NN is_VBZ to_TO allow_VB for_IN the_DT eventual_JJ discontinuation_NN of_IN drug_NN treatment_NN ._.
        Preliminary_JJ evidence_NN ,_, published_VBN by_IN Bruce_NNP Walker_NNP and_CC his_PRP$ colleagues_NNS from_IN Harvard_NNP Medical_NNP
        School_NNP in_IN 
        Nature_NNP in_IN 2000_CD ,_, suggested_VBD that_IN this_DT approach_NN worked_VBD in_IN persons_NNS treated_VBN in_IN
        the_DT earliest_JJS stages_NNS of_IN acute_JJ HIV_NNP infection_NN ._. HIV-_NNP 1_CD viral_JJ loads_NNS in_IN newly_RB infected_JJ patients_NNS
        remained_VBD suppressed_VBN for_IN a_DT median_NN of_IN six_CD months_NNS after_IN therapy_NN had_VBD been_VBN stopped_VBN ._. However_RB ,_, a_DT
        follow_VB up_RB paper_NN ,_, published_VBD this_DT month_NN in_IN 
        PLoS_NNP Medicine_NNP by_IN the_DT same_JJ research_NN group_NN ,_, shows_VBZ that_IN the_DT viral_JJ load_NN
        rebounded_VBD in_IN eight_CD of_IN the_DT 14_CD patients_NNS by_IN one_CD year_NN ._.
        “ The_DT findings_NNS are_VBP very_RB straightforward_JJ and_CC very_RB important_JJ ,_,” comments_VBZ Danny_NNP Douek_NNP from_IN
        the_DT Vaccine_NNP Research_NNP Center_NNP ,_, National_NNP Institutes_NNPS of_IN Health_NNP ,_, United_NNP States_NNPS ,_, who_WP was_VBD not_RB
        involved_VBN in_IN the_DT study_NN ._. “ In_IN almost_RB every_DT case_NN ,_, virus_NN rebounded_VBD and_CC no_DT clinical_JJ benefit_NN from_IN
        the_DT interruption_NN could_MD be_VB determined_VBN ._.”
        Walker_NNP 's_POS team_NN first_RB considered_VBD the_DT possibility_NN of_IN STI_NNP in_IN 1997_CD after_IN they_PRP demonstrated_VBD
        that_IN HAART_NNP given_VBN to_TO patients_NNS recently_RB infected_VBN with_IN HIV_NNP could_MD protect_VB T_NN helper_NN cells_NNS ,_, which_WDT
        are_VBP normally_RB destroyed_VBN in_IN the_DT earliest_JJS stages_NNS of_IN infection_NN ._. They_PRP hypothesized_VBN that_IN early_JJ
        treatment_NN of_IN acute_JJ HIV-_NNP 1_CD infection_NN with_IN HAART_NNP might_MD boost_VB the_DT immune_JJ response_NN ,_, allowing_VBG it_PRP
        to_TO control_VB the_DT HIV-_NNP 1_CD infection_NN without_IN the_DT need_NN for_IN continuous_JJ therapy_NN ._. “ We_PRP did_VBD not_RB know_VB at_IN
        that_DT time_NN whether_IN the_DT T_NN helper_NN cells_NNS would_MD be_VB functional_JJ ,_,” explains_VBZ Walker_NNP ._. “ The_DT only_JJ way_NN
        to_TO tell_VB this_DT was_VBD to_TO stop_VB medications_NNS and_CC see_VB if_IN the_DT immune_JJ response_NN could_MD control_VB the_DT
        virus_NN ._.”
        To_TO test_VB this_DT hypothesis_NNS the_DT researchers_NNS did_VBD an_DT open-label_JJ trial_NN of_IN STIs_NNP ;_: they_PRP published_VBD
        data_NNS from_IN six_CD months_NNS follow-up_JJ in_IN the_DT 
        Nature_NNP paper_NN ._. “ The_DT key_JJ finding_NN was_VBD that_IN we_PRP were_VBD able_JJ to_TO get_VB at_IN least_JJS
        transient_JJ control_NN of_IN virus_NN in_IN all_DT eight_CD persons_NNS studied_VBN ,_, and_CC in_IN five_CD of_IN eight_CD the_DT viral_JJ
        load_NN was_VBD less_JJR than_IN 500_CD copies_NNS (_( very_RB low_JJ !_. )_) at_IN the_DT time_NN of_IN publication_NN ,_,” explains_VBZ Walker_NNP ._.
        However_RB ,_, at_IN that_DT point_NN they_PRP did_VBD not_RB know_VB how_WRB long_JJ the_DT protective_JJ effects_NNS would_MD last_VB ._.
        The_DT first_JJ evidence_NN that_DT protection_NN was_VBD not_RB complete_JJ came_VBD two_CD years_NNS later_RB when_WRB Walker_NNP 's_POS
        team_NN reported_VBD a_DT case_NN of_IN superinfection_NN ;_: one_CD of_IN the_DT patients_NNS in_IN the_DT original_JJ experiment_NN was_VBD
        infected_VBN with_IN a_DT second_JJ strain_NN of_IN HIV_NNP ,_, even_RB though_IN the_DT first_JJ virus_NN was_VBD still_RB well_RB
        controlled_VBN ._. “ This_DT paper_NN was_VBD important_JJ because_IN it_PRP indicated_VBD that_IN the_DT amount_NN of_IN immunity_NN
        might_MD be_VB enough_RB for_IN the_DT person_NN 's_POS own_JJ virus_NN ,_, but_CC might_MD not_RB protect_VB against_IN closely_RB related_VBN
        viruses_NNS circulating_VBG in_IN the_DT population_NN ,_,” says_VBZ Walker_NNP ._.
        The_DT 
        PLoS_NNP Medicine_NNP study_NN adds_VBZ more_JJR concern_NN since_IN it_PRP shows_VBZ that_IN although_IN most_JJS
        persons_NNS can_MD indeed_RB transiently_RB control_VB their_PRP$ own_JJ virus_NN ,_, they_PRP do_VBP so_RB for_IN only_RB a_DT limited_JJ
        amount_NN of_IN time_NN ._. “ We_PRP expanded_VBD the_DT study_NN to_TO 14_CD persons_NNS ,_, and_CC now_RB have_VBP about_IN five_CD years_NNS of_IN
        follow-up_JJ on_IN some_DT of_IN the_DT patients_NNS ,_,” says_VBZ Walker_NNP ._. “ Although_IN we_PRP were_VBD able_JJ to_TO use_VB early_JJ
        treatment_NN and_CC structured_VBN treatment_NN interruption_NN to_TO boost_VB immunity_NN and_CC have_VBP 11_CD of_IN 14_CD
        patients_NNS control_VBP their_PRP$ virus_NN ,_, most_JJS of_IN the_DT persons_NNS ultimately_RB ‘ broke_VBD through_IN ,_,’ meaning_VBG that_IN
        they_PRP had_VBD a_DT recurrence_NN of_IN viremia_NN ._.” At_IN the_DT present_JJ time_NN the_DT researchers_NNS do_VBP not_RB know_VB what_WP
        causes_NNS the_DT loss_NN of_IN viral_JJ control_NN ._.
        Walker_NNP and_CC colleagues_NNS conclude_VBP that_IN treatment_NN interruptions_NNS should_MD probably_RB be_VB avoided_VBN
        outside_IN the_DT setting_NN of_IN controlled_VBN clinical_JJ trials_NNS ,_, whereas_IN Douek_NNP goes_VBZ a_DT step_NN further_JJ :_: “ The_DT
        study_NN shows_VBZ that_IN even_RB early_JJ short-term_JJ treatment_NN and_CC structured_VBN treatment_NN interruptions_NNS ,_,
        using_VBG current_JJ strategies_NNS ,_, impart_VB only_RB transient_JJ benefit_NN and_CC are_VBP unlikely_JJ to_TO serve_VB as_IN a_DT
        reasonable_JJ therapeutic_JJ option_NN in_IN the_DT future_NN ._.”
      
    
  
